Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has soared by 7.42 in relation to previous closing price of 4.45. Nevertheless, the company has seen a gain of 8.14% in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
The 36-month beta value for RLAY is at 1.58. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RLAY is 123.45M, and currently, shorts hold a 12.11% of that float. The average trading volume for RLAY on January 14, 2025 was 2.07M shares.
RLAY’s Market Performance
The stock of Relay Therapeutics Inc (RLAY) has seen a 8.14% increase in the past week, with a 7.90% rise in the past month, and a -27.36% fall in the past quarter. The volatility ratio for the week is 17.37%, and the volatility levels for the past 30 days are at 9.44% for RLAY. The simple moving average for the past 20 days is 7.30% for RLAY’s stock, with a -26.76% simple moving average for the past 200 days.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Buy.” The predicted price for RLAY in the upcoming period, according to Jefferies is $16 based on the research report published on September 10, 2024 of the previous year 2024.
Goldman, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $20. The rating they have provided for RLAY stocks is “Buy” according to the report published on September 10th, 2024.
RLAY Trading at -2.29% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.40% of loss for the given period.
Volatility was left at 9.44%, however, over the last 30 days, the volatility rate increased by 17.37%, as shares sank -4.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.98% lower at present.
During the last 5 trading sessions, RLAY rose by +8.14%, which changed the moving average for the period of 200-days by -36.86% in comparison to the 20-day moving average, which settled at $4.45. In addition, Relay Therapeutics Inc saw 16.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Rahmer Peter, who sale 32,177 shares at the price of $4.30 back on Jan 03 ’25. After this action, Rahmer Peter now owns 325,330 shares of Relay Therapeutics Inc, valued at $138,361 using the latest closing price.
Rahmer Peter, the of Relay Therapeutics Inc, sale 32,156 shares at $4.15 during a trade that took place back on Jan 02 ’25, which means that Rahmer Peter is holding 357,507 shares at $133,447 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -39.27 for the present operating margin
- 0.59 for the gross margin
The net margin for Relay Therapeutics Inc stands at -34.5. The total capital return value is set at -0.44. Equity return is now at value -42.69, with -37.58 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -5.63. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -56.63.
Currently, EBITDA for the company is -374.15 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 69.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.42.
Conclusion
In conclusion, Relay Therapeutics Inc (RLAY) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
